Quebec offered nirsevimab to every infant in the 2024-25 RSV season, and compared those aged 0-5 months with older children who were not eligible. Hospitalisations with a positive RSV test fell by 66%, and emergency visits for acute bronchiolitis by 35%. Between 323 and 746 hospitalisations were estimated to have been prevented over the season.
Why it is interesting: The fall is measured against older children who were not offered nirsevimab, so season strength is allowed for.
Cite this item
BibTeX
Free sign-up. A digest of the new papers twice a week, grouped by domain.